Valuation: Inovio Pharmaceuticals, Inc.

Market Cap 122M 105M 97.79M 89.52M 168M 11.67B 170M 1.16B 451M 5.86B 458M 448M 19.4B P/E 2026 *
-1.46x
P/E 2027 * -2.7x
Enterprise Value 122M 105M 97.79M 89.52M 168M 11.67B 170M 1.16B 451M 5.86B 458M 448M 19.4B EV / Sales 2026 *
183x
EV / Sales 2027 * 2.41x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day-2.48%
1 week+8.26%
Current month+74.30%
1 month+11.32%
3 months-12.59%
6 months-31.79%
Current year-32.18%
1 week 1.04
Extreme 1.04
1.32
1 month 0.56
Extreme 0.5632
1.32
Current year 0.56
Extreme 0.5632
2.03
1 year 0.56
Extreme 0.5632
2.98
3 years 0.56
Extreme 0.5632
14.75
5 years 0.56
Extreme 0.5632
115.08
10 years 0.56
Extreme 0.5632
405.48
Manager TitleAgeSince
Chief Executive Officer 60 2022-05-09
Director of Finance/CFO 62 2002-05-31
Chief Tech/Sci/R&D Officer 60 2022-06-26
Director TitleAgeSince
Chairman 81 2019-01-02
Director/Board Member 69 2016-03-10
Director/Board Member 71 2017-12-05
Date Insider Type Main position Quantity % Market Cap.
2/26/26 Fiscal year

Chief Financial Officer

40,547 0.0590%
2/26/26 Fiscal year

Chief Technology Officer

29,850 0.0434%
2/26/26 Fiscal year

Chief Technology Officer

37,023 0.0539%
Change 5-day change 1-year change 3-year change Capi.($)
-2.48%+8.26%-39.80%-77.90% 122M
+1.09%+5.26%+4.52%+26.24% 51.61B
-1.07%+2.82%+465.96%+586.75% 44.89B
+1.47%+9.79%+35.92%+21.40% 42.77B
+1.44%+7.77%+19.38%+92.75% 42.58B
-0.93%-4.33%+16.18%+53.76% 31.82B
+1.32%+7.30%+33.89%+150.10% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+32.10% 14.76B
+1.28%+5.41%+82.40%+47.43% 14.09B
Average +0.16%+4.82%+69.44%+103.63% 27.66B
Weighted average by Cap. +0.48%+4.72%+99.51%+146.19%

Financials

2026 *2027 *
Net sales 667K 571K 534K 489K 918K 63.79M 930K 6.31M 2.46M 32.04M 2.5M 2.45M 106M 50.61M 43.35M 40.56M 37.13M 69.68M 4.84B 70.6M 479M 187M 2.43B 190M 186M 8.05B
Net income -68.03M -58.27M -54.53M -49.91M -93.67M -6.51B -94.91M -644M -251M -3.27B -255M -250M -10.82B -56.49M -48.39M -45.27M -41.44M -77.78M -5.4B -78.8M -535M -209M -2.71B -212M -207M -8.98B
Net Debt - -
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
Employees
112
Date Price Change Volume
26-08-21 US$1.180 -2.48% 5,015,594
26-08-20 US$1.210 -6.92% 4,139,079
26-08-19 US$1.300 +8.33% 6,970,649
26-08-18 US$1.200 +4.35% 4,745,123
26-08-17 US$1.150 +5.50% 6,487,413
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.180USD
Average target price
3.167USD
Spread / Average Target
+168.36%

Quarterly revenue - Rate of surprise